# EDGAR Filing Document

**Accession Number:** 0001828318
**File Stem:** 0001828318-26-000005
**Filing Date:** 2026-2
**Character Count:** 52434
**Document Hash:** 0a6231cf392cca5c57462e94e4f776da
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001828318-26-000005.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0001828318-26-000005

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260225

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enovix Corp
- **CENTRAL INDEX KEY:** 0001828318
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 853174357
- **FISCAL YEAR END:** 1228

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39753
- **FILM NUMBER:** 26678739

**BUSINESS ADDRESS:**
- **STREET 1:** 3501 W. WARREN AVENUE
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510 695-2350

**MAIL ADDRESS:**
- **STREET 1:** 3501 W. WARREN AVENUE
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Rodgers Silicon Valley Acquisition Corp
- **DATE OF NAME CHANGE:** 20201014

?xml version='1.0' encoding='ASCII'? envx-20260225

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON**, **D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 25, 2026**

**Enovix Corporation**

**(Exact Name of Registrant as Specified in Its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39753** | **85-3174357** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **3501 W Warren Avenue** <br>**Fremont, California** | **94538** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Registrant's Telephone Number, Including Area Code: (510) 695-2350** 

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br>Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | ENVX | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On February 25, 2026, Enovix Corporation (the "Company") issued a press release announcing the release of its financial results for the fourth fiscal quarter and full year 2025. A copy of the press release is attached as Exhibit 99.1 to this report.

The information in this current report on Form 8-K and the exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 8.01 Other Events**

On February 25, 2026, the Company announced that the Company's board of directors authorized an additional repurchase plan (the "2026 Repurchase Plan") for the repurchase of up to $75 million shares of the Company's common stock, $0.0001 par value per share (the "Common Stock"). The 2026 Repurchase Plan is in addition to the repurchase plan previously announced by the Company on July 2, 2025 (the "2025 Repurchase Plan"). As of December 28, 2025, the Company had capacity to repurchase approximately $1.6 million shares of Common Stock remaining under the 2025 Repurchase Plan, and the 2025 Repurchase Plan expires at the end of 2026.

Under the 2026 Repurchase Plan, the Company may repurchase up to $75 million shares of Common Stock from time to time through open market purchases or through privately negotiated transactions, subject to market conditions, applicable legal requirements and other relevant factors. Open market repurchases may be structured to occur in accordance with the requirements of Rule 10b-18. The timing and number of shares of Common Stock repurchased pursuant to the 2026 Repurchase Plan will depend on a variety of factors, including price, general business and market conditions, and alternative investment opportunities.

The 2026 Repurchase Plan does not require the purchase of any minimum number of shares of Common Stock, has no expiration date, and repurchases may be initiated, suspended, or discontinued at any time without prior notice.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | <br>**Description** |
| 99.1 | <u>[Q4 202](envx8k-q42025x2252026ex991.htm)[5](envx8k-q42025x2252026ex991.htm)[and Full Year 202](envx8k-q42025x2252026ex991.htm)[5](envx8k-q42025x2252026ex991.htm)[Financial Results Press Release dated](envx8k-q42025x2252026ex991.htm)</u> <u>February 25, 2026.</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **Enovix Corporation** |
| Date: | February 25, 2026 | By: | /s/ Arthi Chakravarthy |
|  |  |  | Arthi Chakravarthy<br>Chief Legal Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![capturea.jpg](capturea.jpg)

**Enovix Reports Fourth Quarter and Full Year 2025 Results** 

***Lead Smartphone Customer Qualification Progressing***

FREMONT, Calif., February 25, 2026 -- Enovix Corporation (Nasdaq: ENVX) ("Enovix"), a developer and manufacturer of advanced lithium-ion batteries, including proprietary silicon-anode architectures, today reported financial results for the fourth quarter and full year ending 2025. The Company will host a live webcast today, Wednesday February 25<sup>th</sup>, at **5:00 PM ET / 2:00 PM PT** to discuss the results and provide a business update. To register for the webcast, please visit: https://enovix-q4-2025.open-exchange.net/.

**Qualification and Commercialization Progress** 

"Our top priority remains completing smartphone qualification and moving into commercial production," said Dr. Raj Talluri, President and CEO of Enovix. "During the fourth quarter, customer evaluation samples met energy density, fast-charge and safety requirements, and cycle-life performance improved toward customer-defined qualification targets under established protocols."

Cycle-life testing under high power conditions is the key gating requirement to launch our first smartphone battery, and we are executing multiple defined pathways with our lead customer to achieve qualification targets. These include continued optimization of AI-1 recipe variations, as well as alignment on updated silicon-specific protocols that more closely reflect real-world smartphone usage. Successful completion under any of these pathways will enable customer qualification and follow-on commercial shipments.

Smart eyewear devices place even greater emphasis on volumetric energy density due to smaller battery footprints and continuous-on AI workloads. Smart eyewear manufacturers typically require lower cycle-life thresholds for qualification than smartphone manufacturers. Based on ongoing customer engagements, Enovix believes the AI-1 platform already meets or exceeds key technical requirements for multiple smart eyewear applications, positioning this category as a potential early commercialization opportunity.

Dr. Talluri continued, "Customer engagement is also expanding across smart eyewear and other AI-powered applications that require higher energy density in increasingly space-constrained designs. Smart eyewear platforms are progressing toward production readiness, and we have begun receiving initial production demand from our lead customer as devices move toward commercial launch. Our manufacturing organization also continued to make solid progress preparing Fab2 in Malaysia for higher-volume production to support our upcoming commercialization programs."

**Manufacturing Readiness Progress**

During 2025, Enovix improved its production readiness across its global operations to support upcoming commercialization programs:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Global manufacturing operations were unified under Kihong Park, who previously lead Enovix's South Korea manufacturing operations that were established through the Routejade and SETK acquisitions. In addition, Enovix strengthened its advanced manufacturing capabilities with the addition of Ed Casey, who leads Advanced Manufacturing Engineering. Ed brings decades of experience scaling high-volume manufacturing across global production networks, including senior leadership roles at Seagate, Western Digital, and ams OSRAM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our new manufacturing leadership team is sharpening our focus on manufacturing execution as we scale toward high-volume production. At Fab2, we continue to see consistent gains in yield and throughput. While Zone 1 laser dicing currently defines our primary throughput limit, we believe we can resolve this via process optimization and alternative dicing technologies. This path would clear the way for significantly higher production rates as we commercialize. In 2026, we are capable of qualifying other new products and customers in our production lines, and meeting demand for smart eyewear customers.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• China Compulsory Certification (CCC) and Underwriters Laboratories (UL) were secured for AI-1 smart eyewear batteries.

**Fourth Quarter and Full Year 2025 Financial Results** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Record fourth quarter 2025 revenue of $11.3 million, compared to $9.7 million in fourth quarter 2024, and record full-year 2025 revenue of $31.8 million, compared to $23.1 million in 2024, representing 38% year-over-year growth, primarily reflecting defense and industrial shipments. Cells manufactured through Enovix's South Korea operations continue deployment across defense applications including aerial drones, subsea systems and munitions platforms, while next-generation silicon-anode developments position Enovix to support future higher-performance applications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP gross profit was $2.5 million in 4Q25 and $6.1 million for FY2025. Non-GAAP gross profit of $2.9 million in 4Q25 and $7.3 million for FY2025. Full-year non-GAAP gross margin improved to 23%, reflecting operational execution improvements and higher production volumes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net cash used in operating activities of $27.0 million in 4Q25 and $95.3 million for full year 2025, increased from an outflow of $16.0 million in 4Q24 and decreased from $108.6 million for full year 2024. Free cash flow was an outflow of $28.0 million in 4Q25 and $113.5 million for full year 2025, improving from an outflow of $32.3 million in 4Q24 and $184.8 million for full year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash, cash equivalents and marketable securities totaled approximately $621 million at year-end, including approximately $2.0 million of restricted cash, providing liquidity to support qualification completion and commercialization scale-up.

**Fourth Quarter 2025 Financial Summary** 

*(in millions, except per share data and percentages)* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | GAAP | GAAP | GAAP | Non-GAAP | Non-GAAP | Non-GAAP |
| | Q4 2025 | Q4 2024 | YoY Δ | Q4 2025 | Q4 2024 | YoY Δ |
| Revenue | $11.3 | $9.7 | $1.6 | $11.3 | $9.7 | $1.6 |
| Gross profit | $2.5 | $1.1 | $1.4 | $2.9 | $1.2 | $1.7 |
| Gross margin | 22.1% | 11.3% | 10.8pts | 25.7% | 12.4% | 13.3pts |
| Operating expenses | $46.5 | $35.6 | $10.9 | $31.8 | $26.3 | $(5.5) |
| Loss from operations | $(44.0) | $(34.5) | $(9.5) | $(28.9) | $(25.1) | $(3.8) |
| Net cash used in operating activities | $(27.0) | $(16.0) | $(11.0) | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | $(28.0) | $(32.3) | $4.3 |
| Adjusted EBITDA | N/A | N/A | N/A | $(21.7) | $(16.3) | $(5.4) |
| Net loss per share, basic <sup>(1)</sup> | $(0.16) | $(0.19) | $0.03 | $(0.14) | $(0.12) | $(0.02) |
| Weighted average shares, basic <sup>(2)</sup> | 216.3 | 196.6 | 19.7 | 216.3 | 196.6 | 19.7 |
| Net loss per share, diluted <sup>(1)</sup> | $(0.16) | $(0.19) | $0.03 | $(0.14) | $(0.12) | $(0.02) |
| Weighted average shares, diluted<sup>(2)</sup> | 216.3 | 196.6 | 19.7 | 216.3 | 196.6 | 19.7 |

---

(1) Net loss per share attributable to Enovix (2) Weighted average shares attributable to Enovix

------

**Full-Year 2025 Financial Summary** 

*(in millions, except per share data and percentages)* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | GAAP | GAAP | GAAP | Non-GAAP | Non-GAAP | Non-GAAP |
| | FY 2025 | FY 2024 | YoY Δ | FY 2025 | FY 2024 | YoY Δ |
| Revenue | $31.8 | $23.1 | $8.7 | $31.8 | $23.1 | $8.7 |
| Gross profit (loss) | $6.1 | $(2.0) | $8.1 | $7.3 | $0.2 | $7.1 |
| Gross margin | 19.2% | (8.7)% | 27.9pts | 23.0% | 0.9% | 22.1pts |
| Operating expenses | $183.4 | $240.6 | $(57.2) | $120.5 | $137.3 | $16.8 |
| Loss from operations | $(177.3) | $(242.7) | $65.4 | $(113.2) | $(137.1) | $23.9 |
| Net cash used in operating activities | $(95.3) | $(108.6) | $13.3 | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | $(113.5) | $(184.8) | $71.3 |
| Adjusted EBITDA | N/A | N/A | N/A | $(84.0) | $(95.7) | $11.7 |
| Net loss per share, basic <sup>(1)</sup> | $(0.75) | $(1.19) | $0.44 | $(0.54) | $(0.69) | $0.15 |
| Weighted average shares, basic <sup>(2)</sup> | 207.6 | 186.0 | 21.6 | 207.6 | 186.0 | 21.6 |
| Net loss per share, diluted <sup>(1)</sup> | $(0.75) | $(1.19) | $0.44 | $(0.54) | $(0.69) | $0.15 |
| Weighted average shares, diluted <sup>(2)</sup> | 207.6 | 186.0 | 21.6 | 207.6 | 186.0 | 21.6 |

---

(1) Net loss per share attributable to Enovix (2) Weighted average shares attributable to Enovix

**\* \* \* \* \*** 

**Chairman's 2025 Summary** 

T.J. Rodgers, Enovix chairman, commented, "I attend three major Enovix reviews per quarter: the board meeting (six hours), the manufacturing operations review (three hours), and the R&D review (four hours). My 2025 observations follow: 1) we are focusing on the smartphone market because it is huge and demands the very best technology and quality – a superset of what we need, 2) we have two "teaching" smartphone customers that want to qualify us, 3) we have passed 70 of their 75 qualification specifications, and 4) we have identified multiple paths to pass the remaining tests. A single smartphone program from either of our smartphone partners would fill our current Penang manufacturing line, and a few smartphone programs would fill the four lines our plant can house.

Rodgers continued, "Our Penang manufacturing line makes battery qualification samples today limited by a single step, the laser dicing of the battery electrode ribbons from the rolls of anode material (silicon on copper foil) and cathode material (cobalt oxide on aluminum foil). Our overall line yield is measured at 9 steps, whose yields multiply to give overall yield. All but one of those 9 steps have yields of 80% or higher, meaning that the new line is fully functional, except for the laser dicing step, which does yield reasonably, but only at a production rate that is a fraction of the rest of the line. We continue to perfect dicing with multiple laser types and have a Plan B to use a custom mechanical punching tool. Making electrode dicing yield well at high speed is our current major production impediment. While we are working on dicing yield and speed, we are fully capable of qualifying other new products and customers in the very production line they will use.

Rodgers concluded, "We have also made progress in the market. Last quarter we shipped $11.3 million in batteries, primarily from our Korean subsidiary, Routejade, to customers in the defense industry. More importantly, we have successfully sampled multiple major customers in the smart eyewear market. Unlike the large smartphone batteries, smart eyewear batteries must be small enough to fit in the earpieces of the glasses, but still store a lot of energy – and it appears that our first samples meet those requirements. Finally, to validate our customer feedback, we commissioned a third-party benchmark study (posted on our website) comparing our smartphone batteries to the best competitor's, which now have 5%-15% silicon in the anode versus our 100%. That study shows that our energy density of 935 watt-hours per liter remains the best in the industry by 12% - equal to about two years at the industry's learning rate of 7% per year."

------

**Financial Outlook**

*(in millions, except per share data)*

---

| | | | |
|:---|:---|:---|:---|
| | Q1 2026 Guidance<sup>(1)</sup> | Q1 2025 Results | Q4 2025 Results |
| Revenue | $6.5 - 7.5 | $5.1 | $11.3 |
| Non GAAP loss from operations <sup>(2)</sup> | ($29.0 - 32.0) | ($28.0) | ($28.9) |
| Non GAAP net loss per share <sup>(2),(3)</sup> | ($0.14 - 0.18) | ($0.13) | ($0.14) |
| Capital expenditures <sup>(4)</sup> | $9.0 - 11.0 | $6.3 | $1.0 |

---

(1) Our outlook does not include provisions for proposed tax law changes or for the recently enacted tax reform legislation, future asset impairments or for pending legal matters, other than future legal amounts that are probable and estimable. Further, due to their nature, certain income and expense items, such as certain investments, derivative and foreign currency transaction gains or losses, cannot be accurately forecast. Accordingly, we only include such items in our financial outlook to the extent they are reasonably certain. Actual results may differ materially from the outlook; (2) See Appendix for definitions and reconciliations of non-GAAP Gross Profit (Loss), non-GAAP Gross Margin, non-GAAP Operating Loss, Adjusted EBITDA, and Non-GAAP Net Loss Per Share Attributable to Enovix to their nearest comparable GAAP metrics; (3) non-GAAP Net Loss represents non-GAAP Net Loss Per Share Attributable to Enovix; (4) Capital Expenditures reflects cash paid for property, equipment, and manufacturing assets and is a component of our free cash flow calculation. It excludes depreciation, amortization, and other non-cash investing items. It excludes one-time cash outflows related to business acquisitions, such as the $10 million purchase of SETK assets in Q2 2025

**Capital Allocation**

The company's Board of Directors authorized an additional share repurchase program of up to $75 million, providing flexibility in capital allocation while maintaining focus on commercialization investments and manufacturing scale-up. Repurchases, if any, may be made from time to time in the open market, subject to market conditions, legal requirements, and other factors. The program does not require the purchase of any minimum number of shares, has no expiration date, and repurchases may be initiated, suspended, or discontinued at any time without prior notice.

**About Enovix**

Enovix develops and manufactures advanced lithium-ion batteries, including proprietary silicon-anode architectures, for smartphones, smart eyewear, defense, industrial and emerging edge-AI applications. Its proprietary silicon-anode battery architecture enables higher energy density and performance in space-constrained devices while maintaining safety and reliability, supporting commercialization across consumer and industrial markets.

Enovix is headquartered in Silicon Valley with facilities in India, South Korea and Malaysia, servicing customers globally. For more information visit <u>https://enovix.com</u> and follow us on LinkedIn.

**Non-GAAP Financial Measures** 

This press release includes the use of non-GAAP financial measures, which are intended to provide supplemental information regarding our performance. These non-GAAP measures include non-GAAP cost of revenue, non-GAAP gross profit (loss), non-GAAP gross margin, non-GAAP research and development expense, non-GAAP selling, general and administrative expense, non-GAAP operating expenses, non-GAAP income (loss) from operations, EBITDA, adjusted EBITDA, non-GAAP net loss attributable to Enovix shareholders, non-GAAP earnings (loss) per share, free cash flow, and other non-GAAP measures that are included in this press release.

We use these non-GAAP measures to supplement our financial reporting and to evaluate ongoing operations and results, facilitate internal planning and forecasting, and assess performance against prior periods, industry peers, and the broader market. These non-GAAP measures are not prepared in accordance with generally accepted accounting principles (GAAP) and should not be considered as an alternative to GAAP results. Industry peers and other companies may calculate similar non-GAAP measures differently. Non-GAAP financial measures have limitations, including but not limited to, that they exclude certain expenses that are required under GAAP, which adjustments reflect the exercise of judgment by management. We believe that these non-GAAP measures, when considered together with the GAAP results, provide investors with an

------

additional understanding of our operating performance. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the tables at the end of this press release.

While Enovix provides first quarter 2026 guidance for non-GAAP loss from operations, non-GAAP net loss per share and capital expenditures, we are unable to provide without unreasonable effort a GAAP to non-GAAP reconciliation of these projected non-GAAP measures, and we have not provided a quantitative reconciliation in reliance on the unreasonable efforts exception under Item 10(e)(1)(i)(B) of Regulation S-K. Such reconciliation to the corresponding GAAP financial measure cannot be provided without unreasonable effort because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjustments that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to change in fair value of common stock, stock-based compensation and related tax effects, legal costs related to shareholder lawsuit, gain on bargain purchase of assets, acquisition-related costs, and restructuring costs. As a result, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.

**Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial or operating performance and are identified by words such as anticipate, appears, believe, could, enable, estimate, expect, gating requirement, intend, may, might, plan, possible, potential, predict, progress, project, should, support, will, would and similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding: our future operating results, financial position, growth opportunities, and financial outlook and guidance; our commercialization plans, strategy and product development roadmap, including the readiness, performance, timing and customer qualification of our AI-1™ platform and related products; our expectations about our ability to satisfy gating requirements; our belief that successful completion of various pathways will enable customer qualification and follow-on commercial shipments of our AI-1™ smartphone battery; our belief that our AI-1™ platform meets or exceeds key technical requirements for multiple smart eyewear applications and the associated commercialization opportunity; anticipated customer product launches; our expectations about our manufacturing strategy, facility capacity and scale-up plans, including operational and production readiness across various manufacturing lines; our expectations about our ability to improve dicing yield, speed, throughput, performance, and cost efficiency and operational readiness; our belief that organizational changes, including recent hires, will enhance production readiness and ability to produce batteries in high-volume; our internal benchmarking and customer benchmarking of energy density and competitive positioning, including our belief that our AI-1 platform and AI class of batteries represents a shift from innovation to commercialization and our ability to maintain and expand a performance lead over other silicon-doped or conventional battery architectures; our anticipated ability for our liquidity, capital allocation and financing strategies to support qualification completion and commercialization scale-up; and the timing and expected success of achieving technical milestones and production ramp-up readiness.

Risks, uncertainties and assumptions that could cause actual results to differ materially from the results and events anticipated by such forward-looking statements include, but are not limited to: our ability to improve and maintain competitive battery performance metrics, including energy density, cycle life, fast-charging capability, capacity retention and gassing; risks associated with qualification delays or failure to satisfy gating requirements, or that customer programs do not proceed to commercial launch; challenges in scaling manufacturing capacity, improving or sustaining yield and productivity levels, achieving targeted cost reductions or unit economics, or bringing facilities to full operational readiness; our ability to successfully execute an orderly transition within our operations organization; dependence on third-party contract manufacturers, including a Malaysia-based manufacturing partner, and potential concentration risk, disruptions or changes in those relationships; risks arising from our international operations, including regulatory, financial and operational risks, trade restrictions, tariffs, sanctions and geopolitical tensions; supply chain risks, including our ability to secure sufficient quantities of raw materials and components at acceptable costs; our ability to control operating and manufacturing costs; lengthy and unpredictable customer qualification and sales cycles, safety considerations and contractual terms, particularly in defense and other regulated markets; risks related to battery performance, reliability and safety; customer concentration in the defense sector and certain consumer technology markets, such as smartphones and smart eyewear; challenges in forecasting demand, inventory and manufacturing requirements that may result in additional costs and production delays; our history of losses and expectation of continued losses; risks associated with the development and commercialization of products that remain under development and may not be successfully produced at commercial scale; our ability to effectively integrate and derive benefits from acquired businesses; fluctuations in foreign currency exchange rates and

------

interest rates; operational and safety risks associated with manufacturing equipment; intense competition and our ability to keep up with rapid technological change and evolving standards in the battery industry; our ability to attract and retain qualified personnel; the outcome of litigation, regulatory investigations and other legal matters, including the associated legal and other costs; liquidity constraints, capital availability and our ability to service existing debt; our ability to protect and enforce our intellectual property rights; volatility in the trading price of our common stock; changes in tax laws or regulations; the impact of cyber and other information technology or security related incidents on us, our customers or other parties; changes in the political, economic or regulatory environment generally and in the markets in which we operate; and other risks described in the disclosures contained in our filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our annual report on Form 10-K and quarterly reports on Form 10-Q, and other documents that we have filed, or will file, with the SEC. These documents are available in the SEC Filings section of the Investor Relations page at <u>https://ir.enovix.com</u> and at <u>www.sec.gov</u>.

It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not rely on any of the forward-looking statements. Any forward-looking statements in this press release speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For media and investor inquiries, please contact:

**Investor Contact:** 

Robert Lahey

ir@enovix.com

**Chief Financial Officer:** 

Ryan Benton

ryan.benton@enovix.com

------

**ENOVIX CORPORATION** 

**CONSOLIDATED BALANCE SHEETS**

*(In thousands, except share and par value amounts)*

---

| | | |
|:---|:---|:---|
| | **December 28, 2025** | **December 29, 2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $106014 | $272869 |
| &nbsp;&nbsp;&nbsp;Short-term investments | 406026 |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 4421 | 4566 |
| &nbsp;&nbsp;&nbsp;Notes receivable, net | 4012 | 4 |
| &nbsp;&nbsp;&nbsp;Inventory | 13617 | 7664 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 8120 | 9903 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 542210 | 295006 |
| Property and equipment, net | 170263 | 167947 |
| Long-term investments | 106810 |  |
| Customer relationship intangibles and other intangibles, net | 31638 | 36394 |
| Operating lease, right-of-use assets | 11682 | 13479 |
| Goodwill | 12217 | 12217 |
| Other assets, non-current | 4155 | 2126 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $878975 | $527169 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $17818 | $9492 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 13992 | 19843 |
| &nbsp;&nbsp;&nbsp;Accrued compensation | 6219 | 8228 |
| &nbsp;&nbsp;&nbsp;Short-term debt | 9865 | 9452 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 5015 | 3650 |
| &nbsp;&nbsp;&nbsp;Warrant liability | 6578 |  |
| &nbsp;&nbsp;&nbsp;Other liabilities | 5529 | 3036 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 65016 | 53701 |
| Long-term debt, net | 519271 | 169820 |
| Warrant liability, non-current |  | 28380 |
| Operating lease liabilities, non-current | 11244 | 13293 |
| Deferred revenue, non-current | 300 | 3774 |
| Deferred tax liability | 9119 | 8784 |
| Other liabilities, non-current | 14 | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 604964 | 277766 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value; authorized shares of 1,000,000,000; issued and outstanding shares of 216,556,238 and 190,559,335 as of December 28, 2025 and December 29, 2024, respectively  | 22 | 19 |
| &nbsp;&nbsp;&nbsp;Additional paid-in-capital | 1307912 | 1067951 |
| &nbsp;&nbsp;&nbsp;Treasury stock, at cost | (58385) |  |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (508) | (143) |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (977827) | (821086) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Enovix's stockholders' equity | 271214 | 246741 |
| Non-controlling interest | 2797 | 2662 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 274011 | 249403 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $878975 | $527169 |

---

------

**Enovix Corporation**

**Condensed Consolidated Statements of Operations**

*(Unaudited)*

*(In thousands, Except Share and per Share Amounts)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarters Ended** | **Quarters Ended** | **Fiscal Years Ended** | **Fiscal Years Ended** |
| | **December 28, 2025** | **December 29, 2024** | **December 28, 2025** | **December 29, 2024** |
| Revenue | $11265 | $9717 | $31821 | $23074 |
| Cost of revenue | 8764 | 8665 | 25716 | 25119 |
| Gross profit (loss) | 2501 | 1052 | 6105 | (2045) |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | 28074 | 22433 | 110331 | 124506 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 18415 | 13135 | 73028 | 74311 |
| &nbsp;&nbsp;&nbsp;Restructuring cost |  |  |  | 41807 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 46489 | 35568 | 183359 | 240624 |
| Loss from operations | (43988) | (34516) | (177254) | (242669) |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Change in fair value of common stock warrants | 10054 | (5115) | 21832 | 12244 |
| &nbsp;&nbsp;&nbsp;Gain on bargain purchase of assets |  |  | 4761 |  |
| &nbsp;&nbsp;&nbsp;Interest income | 5597 | 2587 | 12998 | 12332 |
| &nbsp;&nbsp;&nbsp;Interest expense | (6411) | (1719) | (21597) | (6787) |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | (160) | 2463 | 1341 | 954 |
| Total other income (expense), net | 9080 | (1784) | 19335 | 18743 |
| Loss before income tax expense (benefit) | (34908) | (36300) | (157919) | (223926) |
| Income tax expense (benefit) | 133 | 1152 | (1312) | (1392) |
| Net loss | (35041) | (37452) | (156607) | (222534) |
| Net gain (loss) attributable to non-controlling interests | (51) | 13 | 134 | (293) |
| Net loss attributable to Enovix | $(34990) | $(37465) | $(156741) | $(222241) |
| Net loss per share attributable to Enovix shareholders, basic <sup>(1)</sup> | $(0.16) | $(0.19) | $(0.75) | $(1.19) |
| Weighted average number of common shares outstanding, basic <sup>(1)</sup> | 216310145 | 196597813 | 207635870 | 186039616 |
| Net loss per share attributable to Enovix shareholders, diluted <sup>(1)</sup> | $(0.16) | $(0.19) | $(0.75) | $(1.19) |
| Weighted average number of common shares outstanding, diluted <sup>(1)</sup> | 216310145 | 196597813 | 207635870 | 186039616 |

---

<sup>(1)</sup> As required by ASC 260, Earnings Per Share, the share and per share amounts in the consolidated financial statements for the periods presented above have been retroactively adjusted to reflect the warrant dividends issued in July 2025.

------

**ENOVIX CORPORATION**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

*(In thousands)*

---

| | | |
|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** |
| | **2025** | **2024** |
| **Cash flows used in operating activities:** |  |  |
| Net loss | $(156607) | $(222534) |
| Adjustments to reconcile net loss to net cash used in operating activities |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation, accretion and amortization | 35112 | 44961 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 49367 | 58837 |
| &nbsp;&nbsp;&nbsp;Change in fair value of common stock warrants | (21832) | (12244) |
| &nbsp;&nbsp;&nbsp;Gain on bargain purchase of assets | (4761) |  |
| &nbsp;&nbsp;&nbsp;Impairment and loss on disposal of long-lived assets |  | 38258 |
| &nbsp;&nbsp;&nbsp;Interest expense (non-cash) | 9222 |  |
| &nbsp;&nbsp;&nbsp;Others | 711 | 448 |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivables | (3935) | (2465) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (5510) | 1073 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (85) | (2211) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 4690 | (7970) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and compensation | 1554 | 3016 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (1987) | (3058) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax liability | (1305) | (2697) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 75 | (2047) |
| Net cash used in operating activities | (95291) | (108633) |
| **Cash flows from investing activities:** |  |  |
| Purchase of property and equipment | (18223) | (76188) |
| Payment for business acquisition | (10000) |  |
| Purchases of investments | (584938) | (31812) |
| Maturities of investments | 74892 | 106621 |
| Net cash used in investing activities | (538269) | (1379) |
| **Cash flows from financing activities:** |  |  |
| Proceeds from issuance of common stock, net of issuance costs |  | 107192 |
| Proceeds from exercise of common stock warrants | 232106 |  |
| Payments of issuance costs related to common stock and warrant dividends | (7077) |  |
| Proceeds from issuance of convertible senior notes and loan borrowing | 360000 | 4572 |
| Payments of debt issuance costs | (11175) |  |
| Purchase of Capped Calls | (45288) |  |
| Repayment of debt | (919) | (209) |
| Proceeds from issuance of common stock under employee stock purchase plan | 1323 | 1506 |
| Payroll tax payments for shares withheld upon vesting of RSUs | (6543) | (7079) |
| Proceeds from the exercise of stock options and issuance of common stock under ATM, net of issuance costs | 3342 | 44771 |
| Repurchase of unvested restricted common stock |  | (4) |
| Repurchase of common stock | (58385) |  |
| Net cash provided by financing activities | 467384 | 150749 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (536) | (1169) |
| Change in cash, cash equivalents, and restricted cash | (166712) | 39568 |
| Cash and cash equivalents and restricted cash, beginning of period | 274691 | 235123 |
| Cash and cash equivalents and restricted cash, end of period | $107979 | $274691 |

---

------

**Net Loss Attributable to Enovix to Adjusted EBITDA Reconciliation**

"EBITDA" is defined as earnings (net loss) attributable to Enovix adjusted for interest income, interest expense, income tax benefit, depreciation and amortization expense. "Adjusted EBITDA" includes additional adjustments to EBITDA such as stock-based compensation expense, change in fair value of common stock warrants, inventory step-up, impairment of equipment, warrant issuance cost, certain legal costs related to our defense of an ongoing securities class action complaint that is outside the ordinary course of business and that we do not consider representative of our performance, and other special items as determined by management which it does not believe to be indicative of its underlying business trends.

These non-GAAP measures may differ from similarly titled measures used by other companies.

Below is a reconciliation of net loss attributable to Enovix on a GAAP basis to the non-GAAP EBITDA and Adjusted EBITDA financial measures for the periods presented below (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarters Ended** | **Quarters Ended** | **Fiscal Years Ended** | **Fiscal Years Ended** |
| | **December 28, 2025** | **December 29, 2024** | **December 28, 2025** | **December 29, 2024** |
| Net loss attributable to Enovix | $(34990) | $(37465) | $(156741) | $(222241) |
| &nbsp;&nbsp;&nbsp;Interest expense (income), net | 814 | (868) | 8599 | (5545) |
| &nbsp;&nbsp;&nbsp;Income tax expense (benefit) | 133 | 1152 | (1312) | (1392) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 8437 | 7544 | 35112 | 44961 |
| EBITDA | (25606) | (29637) | (114342) | (184217) |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | 11394 | 10207 | 49367 | 57621 |
| &nbsp;&nbsp;&nbsp;Change in fair value of common stock warrants | (10054) | 5115 | (21832) | (12244) |
| &nbsp;&nbsp;&nbsp;Inventory step-up |  |  |  | 1907 |
| &nbsp;&nbsp;&nbsp;Restructuring cost <sup>(1)</sup> |  |  |  | 41807 |
| &nbsp;&nbsp;&nbsp;Legal cost related to shareholder lawsuit <sup>(2)</sup> | 2521 | (2007) | 7915 | (541) |
| &nbsp;&nbsp;&nbsp;Warrant issuance cost |  |  | 1378 |  |
| &nbsp;&nbsp;&nbsp;Acquisition cost |  |  | 664 |  |
| &nbsp;&nbsp;&nbsp;Gain on bargain purchase of assets |  |  | (4761) |  |
| &nbsp;&nbsp;&nbsp;Import duty forgiveness |  |  | (2431) |  |
| Adjusted EBITDA | $(21745) | $(16322) | $(84042) | $(95667) |

---

<sup>(1)</sup> $1.2 million of stock-based compensation expense is included in the restructuring cost line of the table above for the fiscal year ended December 29, 2024. None for the fiscal quarters ended December 28, 2025 and December 29, 2024 or the fiscal year ended December 28, 2025.

<sup>(2)</sup> These amounts represent certain legal costs related to the defense of an ongoing securities class action complaint.

------

**Reconciliation of Operating Loss to Non GAAP Operating Loss and Adjusted EBITDA**

Additionally, below is a reconciliation of GAAP operating loss to non-GAAP operating loss and adjusted EBITDA for the periods presented (in thousands).

These non-GAAP measures may differ from similarly titled measures used by other companies.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fiscal Quarters Ended** | **Fiscal Quarters Ended** | **Fiscal Years Ended** | **Fiscal Years Ended** |
| | **December 28, 2025** | **December 29, 2024** | **December 28, 2025** | **December 29, 2024** |
| GAAP loss from operations | $(43988) | $(34516) | $(177254) | $(242669) |
| Stock-based compensation expense <sup>(1)</sup> | 11394 | 10207 | 49367 | 57621 |
| Amortization of intangible assets | 1189 | 1189 | 4757 | 4741 |
| Inventory step-up |  |  |  | 1907 |
| Restructuring cost <sup>(1)</sup> |  |  |  | 41807 |
| Legal cost related to shareholder lawsuit <sup>(2)</sup> | 2521 | (2007) | 7915 | (541) |
| Warrant issuance cost |  |  | 1378 |  |
| Acquisition cost |  |  | 664 |  |
| Non-GAAP loss from operations | $(28884) | $(25127) | $(113173) | $(137134) |
| Depreciation and amortization (excluding amortization of intangible assets) | 7248 | 6355 | 30355 | 40220 |
| Other income (loss), net (excluding import duty forgiveness) | (160) | 2463 | (1090) | 954 |
| Net gain (loss) attributable to non-controlling interest | 51 | (13) | (134) | 293 |
| Adjusted EBITDA | $(21745) | $(16322) | $(84042) | $(95667) |

---

<sup>(1)</sup> $1.2 million of stock-based compensation expense is included in the restructuring cost line of the table above for the fiscal year ended December 29, 2024. None for the fiscal quarters ended December 28, 2025 and December 29, 2024 or the fiscal year ended December 28, 2025.

<sup>(2)</sup> These amounts represent certain legal costs related to the defense of an ongoing securities class action complaint.

------

**Free Cash Flow Reconciliation**

We define "Free Cash Flow" as (i) net cash from operating activities less (ii) capital expenditures, net of proceeds from disposals of property and equipment, all of which are derived from our Consolidated Statements of Cash Flow. It excludes one-time cash outflows related to business acquisitions, including the $10 million purchase of SETK assets in the second quarter of 2025. The presentation of non-GAAP Free Cash Flow is not intended as an alternative measure of cash flows from operations, as determined in accordance with GAAP.

We believe Free Cash Flow is a useful measure for investors because it provides insight into the cash generated or used by our operations after funding capital expenditures, and it helps assess our ability to pursue strategic growth initiatives. We use Free Cash Flow internally to evaluate performance, support decision-making, and measure our progress toward profitability and cash flow breakeven.

This non-GAAP measure may differ from similarly titled measures used by other companies.

Below is a reconciliation of net cash used in operating activities to the Free Cash Flow financial measures for the periods presented below (in thousands):

---

| | | |
|:---|:---|:---|
| | **Fiscal Years** | **Fiscal Years** |
| | **2025** | **2024** |
| Net cash used in operating activities | $(95291) | $(108633) |
| Capital expenditures | (18223) | (76188) |
| Free Cash Flow | $(113514) | $(184821) |

---

------

**Other Non-GAAP Financial Measures Reconciliation** 

*(In Thousands, Except Share and per Share Amounts)*

These non-GAAP measures may differ from similarly titled measures used by other companies.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fiscal Quarters Ended** | **Fiscal Quarters Ended** | **Fiscal Years Ended** | **Fiscal Years Ended** |
| | **December 28, 2025** | **December 29, 2024** | **December 28, 2025** | **December 29, 2024** |
| **Revenue** | $11265 | $9717 | $31821 | $23074 |
| **GAAP cost of revenue** | $8764 | $8665 | $25716 | $25119 |
| Stock-based compensation expense | (440) | (124) | (1197) | (320) |
| Inventory step-up |  |  |  | (1907) |
| **Non-GAAP cost of revenue** | $8324 | $8541 | $24519 | $22892 |
| **GAAP gross profit (loss)** | $2501 | $1052 | $6105 | $(2045) |
| Stock-based compensation expense | 440 | 124 | 1197 | 320 |
| Inventory step-up |  |  |  | 1907 |
| **Non-GAAP gross profit** | $2941 | $1176 | $7302 | $182 |
| **GAAP research and development (R&D) expense** | $28074 | $22433 | $110331 | $124506 |
| Stock-based compensation expense | (5901) | (5082) | (24951) | (24853) |
| Amortization of intangible assets | (416) | (416) | (1663) | (1664) |
| **Non-GAAP R&D expense** | $21757 | $16935 | $83717 | $97989 |
| **GAAP selling, general and administrative (SG&A) expense** | $18415 | $13135 | $73028 | $74311 |
| Stock-based compensation expense | (5053) | (5001) | (23219) | (32448) |
| Amortization of intangible assets | (773) | (773) | (3094) | (3077) |
| Legal cost related to shareholder lawsuit <sup>(2)</sup> | (2521) | 2007 | (7915) | 541 |
| Warrant issuance cost |  |  | (1378) |  |
| Acquisition cost |  |  | (664) |  |
| **Non-GAAP SG&A expense** | $10068 | $9368 | $36758 | $39327 |
| **GAAP operating expenses** | $46489 | $35568 | $183359 | $240624 |
| Stock-based compensation expense included in R&D expense | (5901) | (5082) | (24951) | (24853) |
| Stock-based compensation expense included in SG&A expense | (5053) | (5001) | (23219) | (32448) |
| Amortization of intangible assets | (1189) | (1189) | (4757) | (4741) |
| Restructuring cost <sup>(1)</sup> |  |  |  | (41807) |
| Legal cost related to shareholder lawsuit <sup>(2)</sup> | (2521) | 2007 | (7915) | 541 |
| Warrant issuance cost |  |  | (1378) |  |
| Acquisition cost |  |  | (664) |  |
| **Non-GAAP operating expenses** | $31825 | $26303 | $120475 | $137316 |

---

<sup>(1)</sup> $1.2 million of stock-based compensation expense is included in the restructuring cost line of the table above for the fiscal year ended December 29, 2024. None for the fiscal quarters ended December 28, 2025 and December 29, 2024 or the fiscal year ended December 28, 2025.

<sup>(2)</sup> These amounts represent certain legal costs related to the defense of an ongoing securities class action complaint.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fiscal Quarters Ended** | **Fiscal Quarters Ended** | **Fiscal Years Ended** | **Fiscal Years Ended** |
| | **December 28, 2025** | **December 29, 2024** | **December 28, 2025** | **December 29, 2024** |
| **GAAP loss from operations** | $(43988) | $(34516) | $(177254) | $(242669) |
| Stock-based compensation expense <sup>(1)</sup> | 11394 | 10207 | 49367 | 57621 |
| Amortization of intangible assets | 1189 | 1189 | 4757 | 4741 |
| Inventory step-up |  |  |  | 1907 |
| Restructuring cost <sup>(1)</sup> |  |  |  | 41807 |
| Legal cost related to shareholder lawsuit <sup>(2)</sup> | 2521 | (2007) | 7915 | (541) |
| Warrant issuance cost |  |  | 1378 |  |
| Acquisition cost |  |  | 664 |  |
| **Non-GAAP loss from operations** | $(28884) | $(25127) | $(113173) | $(137134) |
| **GAAP net loss attributable to Enovix** | $(34990) | $(37465) | $(156741) | $(222241) |
| Stock-based compensation expense <sup>(1)</sup> | 11394 | 10207 | 49367 | 57621 |
| Change in fair value of common stock warrants | (10054) | 5115 | (21832) | (12244) |
| Inventory step-up |  |  |  | 1907 |
| Amortization of intangible assets | 1189 | 1189 | 4757 | 4741 |
| Restructuring cost <sup>(1)</sup> |  |  |  | 41807 |
| Legal cost related to shareholder lawsuit <sup>(2)</sup> | 2521 | (2007) | 7915 | (541) |
| Warrant issuance cost |  |  | 1378 |  |
| Interest expense related to the warrant dividend |  |  | 9223 |  |
| Acquisition cost |  |  | 664 |  |
| Gain on bargain purchase of assets |  |  | (4761) |  |
| Import duty forgiveness |  |  | (2431) |  |
| **Non-GAAP net loss attributable to Enovix shareholders** | $(29940) | $(22961) | $(112461) | $(128950) |
| **GAAP net loss per share attributable to Enovix, basic** <sup>(3)</sup> | $(0.16) | $(0.19) | $(0.75) | $(1.19) |
| GAAP weighted average number of common shares outstanding, basic <sup>(3)</sup> | 216310145 | 196597813 | 207635870 | 186039616 |
| **GAAP net loss per share attributable to Enovix, diluted** <sup>(3)</sup> | $(0.16) | $(0.19) | $(0.75) | $(1.19) |
| GAAP weighted average number of common shares outstanding, diluted <sup>(3)</sup> | 216310145 | 196597813 | 207635870 | 186039616 |
| **Non-GAAP net loss per share attributable to Enovix, basic** <sup>(3)</sup> | $(0.14) | $(0.12) | $(0.54) | $(0.69) |
| GAAP weighted average number of common shares outstanding, basic <sup>(3)</sup> | 216310145 | 196597813 | 207635870 | 186039616 |
| **Non-GAAP net loss per share attributable to Enovix, diluted** <sup>(3)</sup> | $(0.14) | $(0.12) | $(0.54) | $(0.69) |
| GAAP weighted average number of common shares outstanding, diluted <sup>(3)</sup> | 216310145 | 196597813 | 207635870 | 186039616 |

---

<sup>(1)</sup> $1.2 million of stock-based compensation expense is included in the restructuring cost line of the table above for the fiscal year ended December 29, 2024. None for the fiscal quarters ended December 28, 2025 and December 29, 2024 or the fiscal year ended December 28, 2025.

<sup>(2)</sup> These amounts represent certain legal costs related to the defense of an ongoing securities class action complaint.

<sup>(3)</sup> As required by ASC 260, Earnings Per Share, the share and per share amounts in the consolidated financial statements for the periods presented above have been retroactively adjusted to reflect the warrant dividends issued in July 2025.

<br>